hantavax
Vaccineexperimental
Hantavirus vaccine is a vaccine that protects in humans against hantavirus hemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome (HPS). The vaccine is considered important as acute hantavirus infections are responsible for significant morbidity and mortality worldwide. It is estimated that about 1.5 million cases and 46,000 deaths occurred in China from 1950 to 2007. The number of cases is estimated at 32,000 in Finland from 2005 to 2010 and 90,000 in Russia from 1996 to 2006. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT02360514)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Orthohantavirus hantanenseImmunity, active
Orthohantavirus hantanense immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHantavirus vaccine ↗
Also known as
- hantavax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02553837 | Phase 3 | Nov 1, 2015 | Green Cross Corporation, Korea University |
| NCT02360514 | Phase 3 | Dec 1, 2007 | Green Cross Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Green Cross Corporation | For profit | 2 | 2 | 1 | 2007 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1